Jack A. Khattar is the founder of Supernus Pharmaceuticals and has served as President and Chief Executive Officer and Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions, including Board Member, President, and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. Prior to that, Mr. Khattar served as an Executive Officer and the Chairman of the Management Committee at CIMA, a drug delivery company that is currently a division of Cephalon. At CIMA, he was also responsible for business development, including the licensing of CIMA's technologies, corporate alliances, and strategic planning.

Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex, and Kodak in various locations, including the United States, Europe, and the Middle East. He is currently a director of Rockville Economic Development Inc. Mr. Khattar earned his degrees in marketing, with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.

Jones W. Bryan, PhD, has served as Vice President of Business Development since 2005. From 2000 to 2005, he served as Vice President of Business Development for Shire Laboratories Inc.
Dr. Bryan was Director of Business Development for Pharmaceutics and Clinical Supply Manufacturing for AAI. He began his career with Schering-Plough in Pharmaceutics and Formulation Development.

Dr. Bryan earned his BS in zoology from Clemson University, his PhD in pharmaceutics from the Medical University of South Carolina, and Executive Management Certificate from the University of North Carolina Kenan-Flagler Business School. He is a member of the Licensing Executives Society and serves on Clemson University's Spiro Institute Entrepreneurship Advisory Board.

Padmanabh P. Bhatt, PhD, has served as our Senior Vice President of Intellectual Property and Chief Scientific Officer since March 2012. Prior to that he served as our Vice President of Pharmaceutical Sciences since 2005. From 2003 to 2005, Dr. Bhatt was Vice President of Advanced Drug Delivery at Shire Laboratories Inc. From 2001 to 2003, Dr. Bhatt served as Vice President of Research and Development and Chief Technology Officer at Point Biomedical Corporation. From 1996 to 2001, he served at ALZA Corporation (now a Johnson & Johnson company) in various positions from Product Development Manager to Director of Technical Development. Prior to that time, Dr. Bhatt has held positions as Research Specialist and Group Leader of Novel Drug Delivery at Dow Corning Corporation (from 1992 to 1996) and Senior Scientist at Hercon Laboratories (from 1989 to 1992).

Dr. Bhatt earned his B.Pharm. and M.Pharm. degrees from the University of Bombay, India. He also holds M.S. and Ph.D. degrees in Pharmaceutical Chemistry from the University of Kansas.

Tami T. Martin, RN, Esq, has served as Vice President of Regulatory Affairs since 2008. Ms. Martin previously held positions as Vice President of Regulatory Affairs at Shire Pharmaceuticals and Manager to Senior Director of Regulatory Affairs at Otsuka America Pharmaceutical, Inc. Ms. Martin also consulted privately for domestic and international clients as President and CEO of Pyramid Regulatory Consulting.

Earlier in her career, Ms. Martin held legal positions at Hogan & Hartson as a member of the Food and Drug Practice Group, and with the Department of Health and Human Services as a staff attorney.
Ms. Martin has served as an instructor for the Johns Hopkins University Masters of Biotechnology and Regulatory Affairs Graduate Degree program, and currently teaches a portion of the United States Regulatory Module for TOPRA (The Organisation for Professionals in Regulatory Affairs).

She earned her BS in nursing from Albright College and a Juris Doctorate degree from Suffolk University. Ms. Martin is a member of the Pennsylvania Bar.

Gregory S. Patrick has served as our Chief Financial Officer since November 2011. From 2010 to 2011, he served as Chief Financial Officer for ROI2. From 2008 to 2010, Mr. Patrick was the Chief Financial Officer at another privately held life sciences company, Bionor Immuno. From 2004 to 2008, he served as the Chief Financial Officer of Sopherion Therapeutics. From 2001 through 2004, he served as Chief Financial Officer for Medimmune, and from 1999 to 2001, as Chief Financial Officer of Ventiv Health. Mr. Patrick served in a variety of positions at Merck & Co. from 1985 through 1999, including Vice President and Controller of Merck's Manufacturing Division, Executive Director of Corporate Planning and Reporting, and Executive Director of Financial Evaluation.

He started his career with Exxon Chemical Company in engineering, and subsequently joined Booz, Allen Hamilton as a management consultant. He holds BS and ME degrees from Rensselaer Polytechnic Institute in Environmental Engineering, and an MBA in Finance from New York University.